17 results about "Apoferritins" patented technology

The invention relates to the field of molecular biology, and discloses a nucleic acid releasing agent for isothermal amplification and a use method of the nucleic acid releasing agent. Comprising the following steps: step 1, preparing a polyoxypropylene polyoxyethylene copolymer diluent, a defoaming agent SE-15 diluent, an ethyl phenyl polyethylene glycol NP-40 diluent, a sodium polyethylene sulfonate diluent and a Proclin300 diluent in sequence through RNA enzyme-free water; and 2, sequentially preparing an ethylenediamine tetraacetic acid disodium salt mother solution, a sodium dodecyl sulfate mother solution and a glycine mother solution through RNA enzyme-free water. Sodium polyethylene sulfonate can be specifically combined with protein amplification inhibitors in a sample to remove mucoprotein, hemoglobin, polysaccharide and other inhibitors in the swab sample, and disodium ethylene diamine tetraacetate can chelate metal ions to reduce the influence of nuclease on target nucleic acid.

Proteases of Group IV (+)ssRNA viruses were found to act on a human sequences in addition to the viral sequences. The identity of the cleavable human sequences is disclosed. Detection of these sequences can act as a diagnostic of infection. It is contemplated that these findings could be employed to facilitate post-translational silencing at the level of protein (e.g., removal of existing proteins), thus serving as a protein analog to CRISPR / Cas9 and RNAi / RISC, and further to enable sequence-specific silencing of host functions without the modification of the host genome.

The present invention relates to a bone graft composition in which a lappaconitine derivative is surface-adsorbed on a scaffold comprising tricalcium phosphate (TCP) and hydroxyapatite (HA). In the composition of the present invention, the osteogenesis-promoting properties of the lappaconitine derivative are combined with the osteoconductivity of the TCP / HA scaffold, thereby improving problems such as high-concentration adverse effects, unstable adsorption patterns, and localized excessive formation, which occur in existing protein-based osteogenic factors.

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and / or proteins. The covalently modified peptides and / or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

The present disclosure relates to pharmaceutical formulations comprising an active ingredient belonging to the amino acid, peptide or protein classes and glycerin as excipient, characterized in that the glycerin has an iron content ≤0.2 ppm and an aldehyde and / or ketone species content ≤5 ppm.

This invention provides novel allergy antigens that are proteins. It also provides polypeptide antigens containing epitopes. [Solution] A novel antigen of a protein to which IgE antibodies in the serum of patients with wheat allergy specifically bind. Furthermore, since the epitope has a relatively short amino acid sequence, if the same amino acid sequence exists in different allergen components, the IgE antibody can bind to multiple allergen components. As a result of the existence of a common epitope in different allergen components, the IgE antibodies of allergic patients bind to both, and the antigen exhibits cross-reactivity.

The invention discloses a method for detecting protein substances in a phlegm-heat clearing injection. The detection method comprises the following steps: (1) preparing a test solution; (2) preparing a sample adding sample solution; (3) preparing a reference solution; and (4) electrophoresis: respectively sucking the test sample solution, the sample adding sample solution and the reference substance solution, applying samples on gradient gel, and carrying out electrophoresis, silver staining and color development. The method provided by the invention is exclusive, sensitive, simple, convenient, efficient and rapid, can specifically detect the protein with the molecular weight of more than 5000, and provides a theoretical basis for the quality control of the phlegm-heat clearing injection and the deep research of the pharmacodynamic material basis through the detection of protein substances.

Disclosed are acid-sensing ion channel (ASIC) inhibitors and their use for treating or inhibiting the development of a condition in which inhibiting an ASIC stimulates or effects treatment or inhibition of the development of the condition. More particularly, this invention relates to proteinaceous ASIC inhibitors and their use for treating or inhibiting the development of a neurological condition, neuronal damage, ischaemia, pain, ischaemia-reperfusion injury, a cancer, chronic kidney disease, acute kidney injury, arthritis and retinal detachment. The ASIC inhibitors are also useful for inhibiting damage to an organ during organ transplantation.

The invention discloses a protein degradation targeting chimera for an EGFR-VHL system. The protein degradation targeting chimera comprises an EGFR binding molecule and a VHL binding molecule, the EGFR binding molecule is any one of proteins as shown in SEQ ID NO.1 to SEQ ID NO.3; the VHL binding molecule is any one of proteins as shown in SEQ ID NO. 4 to 37. The invention also discloses application of the protein degradation targeting chimera in preparation of drugs targeting EGFR and VHL. The invention provides a set of complete calculation design framework, a diversified candidate binding protein library is generated, and finally three high-quality EGFR binding proteins and 34 high-quality VHL binding proteins are obtained and show excellent prediction evaluation indexes. The invention establishes a general framework which is preliminarily verified and is suitable for the rational design of the next generation of protein PROTAC, and lays a foundation for a targeted protein degradation treatment strategy of tumors and other diseases.

The invention discloses a supramolecular group composite peptide-containing antihypertensive composition, which is composed of raw materials and basic energy substrates, the raw materials comprise composite peptide, phytosterol, taurine and the like, and the basic energy substrates comprise proteins, dietary fibers, fatty acids and / or lipids; the composite peptide is composed of Anbenefit milk polypeptide and balsam pear peptide. According to the present invention, the components of the specific types and the specific amounts are selected and compounded, such that the prepared composition has effects of significant cardiac output reducing and blood vessel diameter increasing, and the partial composition can cooperate with valsartan (antihypertensive drug) to achieve effects of synergistic blood pressure reducing so as to provide effects of auxiliary improvement or prevention of blood pressure reducing. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The invention discloses an anti-bubble dispensing device for protein-containing drugs, relates to the technical field of anti-bubble dispensing, and provides the following scheme that the anti-bubble dispensing device comprises a dispensing tank, a driving motor is arranged at the top of the dispensing tank, and a partition plate is fixedly installed on the upper portion of the interior of the dispensing tank; and a liquid separation plate is fixedly mounted on the inner wall of the dispensing tank and located below the partition plate. The liquid distribution plate is trumpet-shaped and provided with holes, medicine can be preliminarily dispersed, the liquid guide plate is matched with the liquid distribution plate, the electric push rod drives the liquid distribution plate to move up and down, the falling state of the medicine is changed, the medicine slowly flows along the tank wall, the bubble generation probability is reduced, the vacuum pump creates a low-air-pressure environment to further inhibit bubbles, and the quality and convenience are improved. The driving motor drives the stirring component to fully mix medicine, quality is guaranteed, the assembly in the supporting frame drives the defoaming teeth to conduct defoaming at different heights according to liquid level signals, the PLC is connected with all the components, automatic control is achieved, and operation convenience is greatly improved.

The invention discloses a blood fat reducing composition containing supramolecular group composite peptide, which is composed of raw materials and basic energy substrates, the raw materials comprise supramolecular group composite peptide, natto freeze-dried powder, black pepper extract and bamboo leaf flavone, and the basic energy substrates comprise proteins, dietary fibers, fatty acids and / or lipids; the composite peptide is composed of soybean peptide and bitter gourd peptide. The composition prepared by compounding the components of specific types and dosages has the effects of remarkably reducing the triglyceride level, reducing the content of low-density lipoprotein cholesterol and increasing the content of high-density lipoprotein cholesterol, and part of the composition can also cooperate with statin western medicines (such as atorvastatin calcium) to achieve the effects of enhancing the effect of reducing blood fat and improving the blood fat content. The effect of assisting in improving or preventing and reducing blood fat is achieved. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

A modified protein comprises a protein moiety and a modified moiety, wherein the protein moiety has a PAS optionally linked to its N-terminus, and the modified moiety is linked directly or via a linker to a cysteine ​​residue in the protein moiety or to a cysteine ​​residue in the optionally chosen PAS, the cysteine ​​residue being either naturally occurring or introduced by mutation. The modified protein not only maintains its original activity but also significantly improves its in vivo half-life. The preparation process for the modified protein is simple and is applicable to the development of a range of therapeutic agents for conditions such as non-alcoholic fatty liver disease, type 2 diabetes, hyperlipidemia, and atherosclerosis.

To provide effective, shelf-stable and safe biological preparations such as peptides and proteins for non-invasive delivery.SOLUTION: The present invention relates to a pharmaceutical composition for transmucosal administration, comprising a peptide drug or a protein drug in combination with an excipient with a pKa value of 12 or higher.SELECTED DRAWING: None

The present invention relates to a method for detecting pathogenic strains resistant to carbapenem antibiotics in a biological sample. The present invention directly identifies carbapenem antibiotic-degrading enzymes, particularly KPC, OXA, NDM, IMP, VIM and / or GES proteins, by mass spectrometry, thereby rapidly determining whether a pathogenic strain is resistant to an antibiotic and the type of resistance-related protein. The present invention discovers the physical and chemical properties of each enzyme in vivo, such as the unique N-terminal cleavage length, methionine residue oxidation and disulfide bond formation based on the type of carbapenem-degrading enzyme, and reflects them in reference mass values, and by doing so, the presence of antibiotic-resistant strains can be more thoroughly detected with high reliability. Therefore, this approach can be effectively used to establish an appropriate antibiotic administration strategy at an early stage of infection.

Described herein protein steroid conjugates that are useful, for example, for the target-specific delivery of glucocorticoids (GCs) to cells.

Compositions and methods for the targeted delivery of therapeutic polypeptides and protein-based therapeutics across the gastrointestinal lining are disclosed. In one aspect, provided is a polypeptide construct comprising (a) a first polypeptide comprising an amino acid sequence that is at least 80% identical to an amino acid sequence selected from any one of SEQ ID NO: 1-40; and (b) a second polypeptide, wherein the second polypeptide is heterologous to the first polypeptide. In one aspect, the heterologous polypeptide is a therapeutic polypeptide.